Evidence map›Paper›PMID 24811059›Full record

ArticlePloS one2014

Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis.

Anjana Bhardwaj, Daniel Rosen, Mei Liu, Yan Liu, Qiang Hao, Nivetha Ganesan, Carol J Etzel, Ashley Gullett, Constance T Albarracin, Isabelle Bedrosian

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Anjana BhardwajDepartment of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Daniel RosenDepartment of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Mei LiuDepartment of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Yan LiuDepartment of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Qiang HaoDepartment of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Nivetha GanesanDepartment of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Carol J EtzelDepartment of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Ashley GullettDepartment of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Constance T AlbarracinDepartment of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Isabelle BedrosianDepartment of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA damage has been thought to be directly associated with the neoplastic progression by enabling mutations in tumor suppressor genes and activating/and amplifying oncogenes ultimately resulting in genomic instability. DNA damage causes activation of the DNA damage response (DDR) that is an important cellular mechanism for maintaining genomic integrity in the face of genotoxic stress. While the cellular response to genotoxic stress has been extensively studied in cancer models, less is known about the cellular response to oncogenic stress in the premalignant context. In the present study, by using breast tissues samples from women at different risk levels for invasive breast cancer (normal, proliferative breast disease and ductal carcinoma in situ) we found that DNA damage is inversely correlated with risk of invasive breast cancer. Similarly, in MCF10A based in vitro model system where we recapitulated high DNA damage conditions as seen in patient samples by stably cloning in cyclin E, we found that high levels of oncogene induced DNA damage, by triggering inhibition of a major proliferative pathway (AKT), inhibits cell growth and causes cells to die through autophagy. These data suggest that AKT-mTOR pathway is a novel component of oncogene induced DNA damage response in immortalized 'normal-like' breast cells and its suppression may contribute to growth arrest and arrest of the breast tumorigenesis.

Indexed as

DNA DamageOncogenesSignal TransductionAutophagyBreast NeoplasmsCarcinogenesisCell Line, TumorCell ProliferationCyclin EFemaleHumansMammary Glands, HumanNeoplasm InvasivenessProto-Oncogene Proteins c-aktRiskTOR Serine-Threonine KinasesCyclin EMTOR protein, humanProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Identifiers

PMID24811059
PMCPMC4014598
OpenAlexW2135917539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.